Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 34851401.
- Also identified by DOI 10.1001/jamanetworkopen.2021.36697 and PMC identifier 8637249.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab.
Medical subject headings
- COVID-19
- Hospitalization
- Immunologic Factors
- Multiple Sclerosis
- Rituximab
- Severity of Illness Index